Next, we aimed to quantify the in vivo angiogenic activity on the CAM engrafted with lung cancer cells with Bevacizumab treatment [25, 26], which is known to inhibit VEGF-induced vascularization. This evidence concerns the gene VEGFA and lung carcinoma.